Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

The HYPODD study was a double-blind placebo-controlled trial aiming to assess the effects of cholecalciferol treatment in patients with well-controlled hypertension and hypovitaminosis D (25OHD levels < 50 nmol/L).

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Double-blind reported · Mixed research settings

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

The HYPODD study was a double-blind placebo-controlled trial aiming to assess the effects of cholecalciferol treatment in patients with well-controlled hypertension and hypovitaminosis D (25OHD levels < 50 nmol/L).

Source: Abstract.

In addition to this clinical trial, we also evaluated the effects of cholecalciferol and calcitriol treatment on miR-21 expression in vivo and in vitro, respectively.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study

Study design awaiting verification · Nutrients · 2022

Original publication title

Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study

Domenico Rendina; Lanfranco D′Elia; Veronica Abate; Andrea Rebellato; Ilaria Buondonno; Mariangela Succoio; Fabio Martinelli; Riccardo Muscariello; Gianpaolo De Filippo; Patrizia D′Amelio; Francesco Fallo; Pasquale Strazzullo; Raffaella Faraonio

© 2022 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

The vitamin D and microRNA (miR) systems may play a role in the pathogenesis of cardiometabolic disorders, including hypertension. The HYPODD study was a double-blind placebo-controlled trial aiming to assess the effects of cholecalciferol treatment in patients with well-controlled hypertension and hypovitaminosis D (25OHD levels < 50 nmol/L). In addition to this clinical trial, we also evaluated the effects of cholecalciferol and calcitriol treatment on miR-21 expression in vivo and in vitro, respectively. Changes in the cardiovascular risk profiles were evaluated in HYPODD patients treated with cholecalciferol (C-cohort) or with placebo (P-cohort).

The miR-21circulating levels were measured in four C-cohort patients and five P-cohort patients. In vitro, the miR-21 levels were measured in HEK-293 cells treated with calcitriol or with ethanol vehicle control. Cholecalciferol treatment increased 25OHD levels and reduced parathormone, total cholesterol, and low-density lipoprotein cholesterol levels in C-cohort patients, whereas no significant changes in these parameters were observed in P-cohort patients. The miR-21 circulating levels did not change in the C: or the P-cohort patients upon treatment. Calcitriol treatment did not affect miR-21 levels in HEK-293 cells.

In conclusion, hypovitaminosis D correction ameliorated the cardiovascular risk profiles in hypertensive patients treated with cholecalciferol but did not influence the miR-21 expression.

Authors’ abstract

The vitamin D and microRNA (miR) systems may play a role in the pathogenesis of cardiometabolic disorders, including hypertension. The HYPODD study was a double-blind placebo-controlled trial aiming to assess the effects of cholecalciferol treatment in patients with well-controlled hypertension and hypovitaminosis D (25OHD levels < 50 nmol/L). In addition to this clinical trial, we also evaluated the effects of cholecalciferol and calcitriol treatment on miR-21 expression in vivo and in vitro, respectively. Changes in the cardiovascular risk profiles were evaluated in HYPODD patients treated with cholecalciferol (C-cohort) or with placebo (P-cohort).

The miR-21circulating levels were measured in four C-cohort patients and five P-cohort patients. In vitro, the miR-21 levels were measured in HEK-293 cells treated with calcitriol or with ethanol vehicle control. Cholecalciferol treatment increased 25OHD levels and reduced parathormone, total cholesterol, and low-density lipoprotein cholesterol levels in C-cohort patients, whereas no significant changes in these parameters were observed in P-cohort patients. The miR-21 circulating levels did not change in the C: or the P-cohort patients upon treatment. Calcitriol treatment did not affect miR-21 levels in HEK-293 cells.

In conclusion, hypovitaminosis D correction ameliorated the cardiovascular risk profiles in hypertensive patients treated with cholecalciferol but did not influence the miR-21 expression.

Publication and source details

Original title: Vitamin D Status, Cardiovascular Risk Profile, and miRNA-21 Levels in Hypertensive Patients: Results of the HYPODD Study

Domenico Rendina; Lanfranco D′Elia; Veronica Abate; Andrea Rebellato; Ilaria Buondonno; Mariangela Succoio; Fabio Martinelli; Riccardo Muscariello; Gianpaolo De Filippo; Patrizia D′Amelio; Francesco Fallo; Pasquale Strazzullo; Raffaella Faraonio

Nutrients · 2022

* Correspondence: raffaella.faraonio@unina.it
†

These authors contributed equally to this work.

© 2022 by the authors.2022https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).SIIA research2011Società Italiana Osteoporosi, Malattie del Metabolismo Minerale e dello Scheletro (SIOMMMS) research2014HYPODD is a no-profit study. The study costs are partially covered by a SIIA research grant 2011 (to L.D.) and by a Società Italiana Osteoporosi, Malattie del Metabolismo Minerale e dello Scheletro (SIOMMMS) research grant 2014 (to R.M.).

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T09:54:09.084506+00:00

DOI: 10.3390/nu14132683 · PMC9268320